Dara Botts
Family · Lebanon, TNNPI 1982826004
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $30,091 of the $47,222 with a category attached, or 63.7%. Novo Nordisk accounts for 66.4% of it on its own, with 56 other manufacturers making up the rest. Reporting peaked in 2022 at $21,643 and has fallen 89.9% since, to $2,188 in 2025. Among family clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 578 payments — averaging $81.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$31K
- Zealand Pharma US, Inc.$5K
- Corcept Therapeutics$2K
- AstraZeneca$987
- Lilly USA, LLC$885
- BETA Bionics, Inc.$686
- plus $6K from 51 others
What the payments were for
- Speaking & faculty fees$30,09164%
- Travel & lodging$3,9188%
- Food & beverage$13,18728%
- Education$260%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$16,968
- Ozempic$11,011
- ZEGALOGUE$3,851
- Korlym$1,658
- V-GO DISPOSABLE INSULIN DELIVERY$916
- iLet Bionic Pancreas$371
- TZIELD$246
- CeQur Simplicity$170
- LOKELMA$169
- FARXIGA$169
- NEXLIZET$101
- NEXLETOL$101
How this compares
$47,222 in reported general payments places this provider in the 95th percentile of 6,706 family providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tresiba Flextouch U-100Insulin Degludec | 154 | $121,031 |
| JardianceEmpagliflozin | 112 | $87,388 |
| TrulicityDulaglutide | 80 | $83,925 |
| OzempicSemaglutide | 78 | $74,484 |
| Tresiba Flextouch U-200Insulin Degludec | 57 | $64,324 |
| FarxigaDapagliflozin Propanediol | 70 | $51,259 |
| RybelsusSemaglutide | 29 | $46,850 |
| MounjaroTirzepatide | 38 | $46,818 |
| Xigduo XrDapaglifloz Propaned/Metformin | 54 | $44,394 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 56 | $33,725 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 29 | $27,134 |
| Humalog Kwikpen U-100Insulin Lispro | 48 | $25,449 |
| Humulin R U-500Insulin Regular, Human | 13 | $24,362 |
| Novolog FlexpenInsulin Aspart | 66 | $18,365 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $15,601 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $885 | $144,890198 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $31,348 | $133,417163 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $133 | $114,523141 claims |
| AstraZenecaFarxiga, Byetta | $987 | $61,29182 claims |
| AbbVieSynthroid | $327 | $9,520148 claims |
| Sanofi-aventis U.S. LLCLantus | $549 | $95513 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $16 | $29457 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,706 family providers in Tennessee.
Other family in Lebanon
- Kimberly FeltsLebanon$64K
- Stacy BrownMt Juliet$719K
- Dana WebberKnoxville$499K
- Brandy BiedermanHixson$448K
- Cynthia MillerMurfreesboro$384K
- Tamera ThoenerNashville$254K
- April SwonerHermitage$246K
- Jennifer WilliamsNashville$213K
- Chantil JeffreysGermantown$195K
- Laura PorchCordova$148K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.